These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 9604303

  • 1. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
    Inoue K, Yamazaki H, Shimada T.
    Xenobiotica; 1998 Apr; 28(4):403-11. PubMed ID: 9604303
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
    De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA.
    Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
    [Abstract] [Full Text] [Related]

  • 6. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
    Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S.
    Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
    [Abstract] [Full Text] [Related]

  • 7. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H.
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [Abstract] [Full Text] [Related]

  • 8. Rapid detection of CYP2C18 genotypes by real-time fluorescence polymerase chain reaction.
    Mizugaki M, Hiratsuka M, Agatsuma Y, Matsubara Y, Fujii K, Kure S, Narisawa K.
    J Pharm Pharmacol; 2000 Feb; 52(2):199-205. PubMed ID: 10714950
    [Abstract] [Full Text] [Related]

  • 9. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
    Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M.
    Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
    [Abstract] [Full Text] [Related]

  • 10. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.
    de Morais SM, Schweikl H, Blaisdell J, Goldstein JA.
    Biochem Biophys Res Commun; 1993 Jul 15; 194(1):194-201. PubMed ID: 8333835
    [Abstract] [Full Text] [Related]

  • 11. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J, Thum T.
    Clin Chem; 2002 Sep 15; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract] [Full Text] [Related]

  • 12. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA.
    Pharmacogenetics; 1997 Feb 15; 7(1):59-64. PubMed ID: 9110363
    [Abstract] [Full Text] [Related]

  • 13. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N.
    Epilepsia; 1998 Dec 15; 39(12):1317-23. PubMed ID: 9860067
    [Abstract] [Full Text] [Related]

  • 14. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase.
    Hersberger M, Marti-Jaun J, Rentsch K, Hänseler E.
    Clin Chem; 2001 Apr 15; 47(4):772-4. PubMed ID: 11274039
    [No Abstract] [Full Text] [Related]

  • 15. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG.
    Fundam Clin Pharmacol; 2007 Aug 15; 21(4):419-26. PubMed ID: 17635181
    [Abstract] [Full Text] [Related]

  • 16. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
    Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M.
    Eur J Clin Pharmacol; 1997 Aug 15; 52(5):391-6. PubMed ID: 9272410
    [Abstract] [Full Text] [Related]

  • 17. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J.
    Pharmacogenetics; 2002 Mar 15; 12(2):91-2. PubMed ID: 11875362
    [No Abstract] [Full Text] [Related]

  • 18. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN, Roots I.
    Eur J Clin Pharmacol; 2003 Aug 15; 59(4):303-12. PubMed ID: 12879168
    [Abstract] [Full Text] [Related]

  • 19. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
    Nasu K, Kubota T, Ishizaki T.
    Pharmacogenetics; 1997 Oct 15; 7(5):405-9. PubMed ID: 9352578
    [No Abstract] [Full Text] [Related]

  • 20. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG.
    Pharmacogenetics; 2002 Mar 15; 12(2):111-9. PubMed ID: 11875365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.